MannKind Corporation suffered a blow this morning, with the market not reacting kindly to the FDA’s declination of their New Drug Application (NDA) for Tyvaso DPI – a new drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension in regards to interstitial lung disease.
Following the early morning public release, MannKind stock has seen a sharp 20% sell-off in reaction to the news. The company – specialists in the development and commercialization of inhalable therapeutic products for those suffering from endocrine and orphan lung diseases – has recorded noticeable gains over the last year, only to be hit hard with this morning’s NDA denial.
Unfortunately for Mannkind and its stakeholders, the NDA was declined by the FDA based on a ‘deficiency’ relating to an open inspection problem at one of the third-party analytical testing centers – more specifically, for treprostinil drug substance, the active ingredient in the anticipated drug Tyvaso DPI.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Michael Castagna, CEO of MannKind Corporation remains optimistic:
“We continue to build pre-launch inventory of Tyvaso DPI and look forward to supporting United Therapeutics’ efforts in securing approval of Tyvaso DPI in the coming months”
Although the FDA issued a firm blow to MannKind stock, the company still looks to stay on its upwards trend. With work in place to ensure Tyvaso DPI is approved in the near future, this could prove as a mere pinprick in the company’s overall growth model.
Should You Invest in MannKind Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
